Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$75.00
Provider: GlobalData
$50.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioPorto A/S Updates on NGAL Patent Processing of Appeal in Opposition Case


Thursday, 23 May 2013 05:01am EDT 

BioPorto A/S announced with reference to announcement from 2012 that the European Patent Office (EPO) has set the date of processing of the appeal concerning rejection of BioPorto’s NGAL cutoff patent, issued in Europe. The case is set at the EPO Boards of Appeal on August 27, 2013. The decision specifying that the patent is to be withdrawn is based on an assessment by the EPO’s Opposition Division that the patent is insufficiently described (Art. 83 of the EPC). In BioPorto's view EPO's argument is based on an erroneous calculation of the specificity. The Company also announced that additional material has been submitted and the EPO Boards of Appeal can issue a preliminary and non-binding opinion prior to the proceedings. If so, BioPorto will evaluate the preliminary opinion when it has been issued. 

Company Quote

2.44
-0.01 -0.41%
23 Jul 2014